Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab compared to PD-L1 at the upcoming National ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...

Researchers found that T cells recognize neoself-antigens -- abnormal, unfolded host proteins presented by major histocompatibility complex II (MHC-II) lacking the invariant chain -- as non-self ...

It is well known that the biggest genetic risk factor for the autoimmune disease systemic lupus erythematosus (SLE) is major histocompatibility complex class II (MHC-II). What remains unclear is the ...

MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...

MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...